FMP
Metacrine, Inc.
MTCR
NASDAQ
Inactive Equity
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
0.581 USD
-0.0076 (-1.31%)
About
ceo
Mr. David M. Maggio
sector
Healthcare
industry
Biotechnology
website
https://www.metacrine.com
exchange
NASDAQ
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
CIK
0001634379
ISIN
US59101E1038
CUSIP
59101E103
Address
3985 Sorrento Valley Boulevard
Phone
858 369 7800
Country
US
Employee
10
IPO Date
Sep 16, 2020
Summary
CIK
0001634379
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
59101E103
ISIN
US59101E1038
Country
US
Price
0.58
Beta
-0.74
Volume Avg.
52.47k
Market Cap
25.48M
Shares
-
52-Week
0.303-0.5905
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.56
P/B
-
Website
https://www.metacrine.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MTCR News
It looks like there's no news available.
